[No HCV seroconversion in hemophilia following substitution with virus-inactivated coagulation factor VIII and IX concentrates].
Since 1986 the factor VIII and IX concentrates of the Central Laboratory, Swiss Red Cross Blood Transfusion Service have been virus inactivated with tri-(n-butyl) phosphate and Tween 80. Clinical studies had shown that both preparations were well tolerated and hemostatically effective; no HIV infection was transmitted. However, safety from transmission of non-A/non-B hepatitis could not be shown since the study included no previously untreated patients. In the meantime, a laboratory test has become available which allows retrospective testing for anti-hepatitis C antibodies in frozen sera of the study patients. 5 of the 26 patients, observed during a 2-year follow-up study, had no HCV antibodies before entering the long-term trial. During this trial, each of these 5 patients substituted an average quantity of 40,200 coagulation factor units (7500-69,000) from 45 production lots. None of these 5 patients developed anti-HCV antibodies, nor did any of them show clinical signs of infection with hepatitis. This suggests that virus inactivation using solvent/detergent treatment reduces the risk of transmission of HCV.
Perret
B A
BA
Zentrallaboratorium Blutspendedienst SRK, Bern.
Morell
A
A
Bütler-Brunner
E
E
Burckhardt
J J
JJ
D001778:Blood Coagulation Disorders / Q000276:immunology / Q000628:therapy*; D001803:Blood Transfusion; D016174:Hepacivirus / Q000187:drug effects* / Q000276:immunology; D006508:Hepatitis Antibodies / Q000302:isolation & purification; D006526:Hepatitis C / Q000517:prevention & control / Q000635:transmission*; D006801:Humans; D010755:Organophosphates / Q000494:pharmacology; D011136:Polysorbates / Q000494:pharmacology
D006508:Hepatitis Antibodies; D010755:Organophosphates; D011136:Polysorbates; C009524:tributyl phosphate
Keine HCV-Serokonversion bei Hämophilen nach Substitution mit Viren-inaktivierten Gerinnungsfaktor VIII- und IX-Konzentraten.